Professor of Dermatology, University Utah
Dermatology
Dr. Gerald G. Krueger, MD
|
|
Give Review
Gerald Krueger practices Dermatology. He researched medicine at Loma Linda University School of Medicine. He has 3 awards "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FAAD)". Dr. Gerald G. Krueger is a published doctor and has 63 publications published. The lastest was: 'microRNAs in Psoriasis.' Gerald Krueger is registered with Medicare.
Publications
- microRNAs in Psoriasis.
- Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 ye...
- WITHDRAWN: Experience with ustekinumab in patients with Psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessm...
- Onset of psoriatic arthritis during ustekinumab treatment for Psoriasis: a case series of seven patients.
- Fine mapping of eight Psoriasis susceptibility loci.
- Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe Psoriasis in the clinical setting.
- Work Productivity Loss and Fatigue in Psoriatic Arthritis.
- Patient-reported outcomes for psoriasis patients with clear versus almost clear Skin in the clinical setting.
- Palmoplantar Psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque Psoriasis.
- Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a lon...
- Patient Satisfaction with Treatments for Moderate-to-Severe Plaque Psoriasis in Clinical Practice.
- Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin...
- Product of the Physician Global Assessment and body surface area: A simple static measure of Psoriasis severity in a longitudinal cohort.
- Psoriasis and the obesity epidemic: the effect of weight Loss.
- Patient reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: Findings through 2 years of th...
- Limitations in Screening Instruments for Psoriatic Arthritis: A Comparison of Instruments in Patients with Psoriasis.
- Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe Psoriasis.
- Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.
- Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe Psoriasis.
- Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extens...
- Consensus guidelines for the management of plaque Psoriasis.
- Genome-Wide Meta-Analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL.
- A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis.
- Dermatologist preferences for first-line therapy of moderate to severe Psoriasis in healthy adult patients.
- Carriers of rare missense variants in IFIH1 are protected from Psoriasis.
- Genome-wide association analysis identifies three Psoriasis susceptibility loci.
- Obesity in early adulthood as a risk factor for psoriatic arthritis.
- Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking.
- International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of Skin, joints, nails, and dactylitis.
- Multiple Loci within the major histocompatibility complex confer risk of Psoriasis.
- A series of critically challenging case scenarios in moderate to severe Psoriasis: a Delphi consensus approach.
- Plaque thickness and morphology in Psoriasis vulgaris associated with therapeutic response.
- Psoriatic arthritis is a strong predictor of sleep interference in patients with Psoriasis.
- Psoriasis bench to bedside: genetics meets immunology.
- Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficac...
- Genetic variations in cytokines and cytokine receptors associated with Psoriasis found by genome-wide association.
- Further genetic evidence for three Psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22.
- What the National Psoriasis Foundation means to dermatologists and our patients.
- From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for Psoriasis.
- Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe Atopic dermatitis.
- A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as Psoriasis-risk genes.
- Observations of Psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque Psoriasis, and the...
- An analysis of select pathogenic messages in lesional and non-lesional psoriatic Skin using non-invasive tape harvesting.
- Patients with Psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
- An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in Psoriasis patients who have received up to nine courses of therapy.
- Impact of obesity and smoking on Psoriasis presentation and management.
- Etanercept improves the health-related quality of life of patients with Psoriasis: results of a phase III randomized clinical trial.
- The remittive effects of alefacept.
- Current concepts and review of alefacept in the treatment of Psoriasis.
- FGF-7 expression enhances the performance of bioengineered Skin.
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of Psoriasis.
- Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod.
- Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in Psoriasis treatment.
- Keratoderma blennorrhagicum.
- A randomized trial of etanercept as monotherapy for Psoriasis.
- The effect of Hair color on the incorporation of codeine into human Hair.
- Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
- Development and use of alefacept to treat Psoriasis.
- Efficacy of acitretin and commercial tanning bed therapy for Psoriasis.
- A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp Psoriasis.
- Clinical features of psoriatic arthritis.
- Induction of dramatic hyperpigmentation in a patient with generalized Lichen planus treated with re-PUVA.
Schools
Loma Linda University School Of Medicine
Fitzsimons Army Med Center
University Of Co School Of Med
Procedures Preformed
- Acne Surgery
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
- Excision of Benign Skin Lesion
- View All
Conditions Treated
- Acne
- Actinic Keratosis
- Athlete's Foot
- Atopic Dermatitis (Eczema)
- View All
Doctors Specialties
- Dermatology
Accepted Insurances
- Choice Plus POS II
- Altius Health Plans
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- GEHA
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Fellow (FAAD)
Education
-
University of Colorado -
Loma Linda University School of Medicine
Hospital
-
University of Utah Health Care - Hospital and Clinics
Drug Facts
| NPI NUMBER | 1578661302 | |
| NPPES Provider LastName | KRUEGER | |
| NPPES Provider FirstName | GERALD | |
| NPPES Provider ZIPCode | 841321100 | |
| NPPES Provider State | UT | |
| Specialty Description | Dermatology | |
| Total Claim Count | 945.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578661302 |
| Last Name Of The Provider | KRUEGER |
| First Name Of The Provider | GERALD |
| View All |
Similar Doctors
|
|
Dr. John L. Bezzant, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Douglas Woseth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline Panko, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Leonard J. Swinyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dee M. Rasmussen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy L. Matis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Angela K. Brimhall, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lindsay H. Wilson, MD |
|
|
Dr. Justin F. Thulin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ivan D. Flint, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah E. Cipriano, MD
This Doctor is OpenDoctor Recommended.
|
|
Laurie Ellis, NP |